

- 9 -

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:-

1. A tablet for use in a drip tray, the tablet including:
 - an excipient selected so that the tablet will not fully dissolve in water at ambient temperature for a period of at least one month;
 - 5 at least 500 ppm of a biocide;
 - at least one enzyme; and
 - enzyme preserving means for maintaining enzyme activity in a moist environment.
- 10 2. A tablet according to claim 1 wherein the excipient is selected such that the tablet will not fully dissolve in water at ambient temperature for a period of at least 6 months.
- 15 3. A tablet according to claim 1 wherein the excipient is selected such that the tablet will not fully dissolve in water at ambient temperature for a period of at least 12 months.
4. A tablet according to any one of the preceding claims wherein the excipient includes one or more compounds selected from the group consisting of poly 20 vinyl alcohols, high molecular weight polyethylene glycols, high molecular weight polypropylene glycols, esters or partial esters of polyethylene glycols or of polypropylene glycols, and high molecular weight thermoplastic surfactants.
- 25 5. A tablet according to claim 4 wherein the excipient includes one or more high molecular weight thermoplastic surfactants compounds selected from the group consisting of polyoxyethylene condensates, polyoxypropylene condensates, polyoxyethylene-polyoxypropylene copolymers with appropriate hydrophobes, and combinations thereof.

- 10 -

6. A tablet according to any one of the preceding claims wherein the at least one enzyme is selected from the group consisting of proteolytic and hydrolase enzymes.
- 5 7. A tablet according to any one of the preceding claims wherein the enzyme preserving means includes a boron compound.
- 10 8. A tablet according to claim 7 wherein the boron compound is present in a concentration sufficient to maintain enzyme activity for at least three months during use.
9. A tablet according to any one of the preceding claims wherein the excipient comprises 2% to 95% by weight of the tablet.
- 15 10. A tablet according to any one of the preceding claims wherein the excipient comprises 10% to 80% by weight of the tablet.
11. A tablet according to any one of claims 1 to 9 wherein the excipient comprises 20% to 60% by weight of the tablet.
- 20 12. A tablet according to any one of the preceding claims wherein the at least one enzyme comprises up to 20% by weight of the tablet.
13. A tablet according to any one of the preceding claims wherein the at least one enzyme comprises up to 10% by weight of the tablet
- 25 14. A tablet according to any one of claims 1 to 12 wherein the at least one enzyme comprises up to 5% by weight of the tablet.
- 30 15. A tablet according to any one of claims 1 to 12 wherein the at least one enzyme comprises up to 3% by weight of the tablet.

- 11 -

16. A tablet according to any one of the preceding claims wherein the enzyme preserving means is present in an amount of from 0.1% to 10% by weight of the tablet.
- 5 17. A tablet according to any one of the preceding claims wherein the enzyme preserving means is present in an amount of from 0.1% to 3% by weight of the tablet.
- 10 18. A tablet according to any one of the preceding claims wherein the biocide is present in an amount of from 0.1% to 20% by weight of the tablet
- 15 19. A tablet according to any one of the preceding claims wherein the biocide is present in an amount of from 0.5% to 10% by weight of the tablet.
- 20 20. A tablet according to any one of claims 1 to 18 wherein the biocide is present in an amount of from 1% to 5% by weight of the tablet.
21. A tablet according to any one of the preceding claims further including a surfactant.
- 20 22. A tablet according to any one of the preceding claims when made in a tablet press.
- 25 23. A tablet according to any one of the claims 1 to 21 when made by a process including the step of moulding.
24. A tablet according to any one of the claims 1 to 21 when made by a process including the step of extrusion.
- 30 25. A tablet according to any one of the claims 1 to 21 when provided with slow release encapsulation.

- 12 -

26. A method for inhibiting the growth of a biofilm in a drip tray or the like, including the step of adding to the tray, a tablet according to any one of the preceding claims.
- 5 27. A tablet substantially as herein described with reference to any one of the examples but excluding any comparatives.
28. A method substantially as herein described with reference to any one of the examples but excluding any comparatives.

10